![](/img/cover-not-exists.png)
Disease stabilization versus response after bevacizumab treatment in recurrent ovarian cancer: How do we determine clinical efficacy?
Fuh, K.C., Secord, A.A., Bevis, K.S., Huh, W.K., Blansit, K., Rosenfeld, E., Hu, L., Previs, R.A., Gardner, A.B., Kapp, D.S., Chan, J.K.Volume:
137
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2015.01.130
Date:
April, 2015
File:
PDF, 53 KB
english, 2015